Navigation Links
Cell Therapeutics' Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
Date:5/30/2012

SEATTLE, May 30, 2012 /PRNewswire/ -- Aequus BioPharma, Inc. ("Aequus"), a majority owned subsidiary of Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), announced today that its GlycoPolymer technology proof of concept studies, featuring recent data with their AQB-101 drug candidate, was selected for an oral presentation at the 9th International Symposium for Polymer Therapeutics meeting.  The meeting will be held on May 28-30, 2012, at the Centro de Investigacion Principe Felipe in Valencia, Spain. 

Stewart D. Chipman, Ph.D., the Chief Scientific Officer and President of Aequus, is scheduled to present the data on Wednesday, May 30, 2012, during the "New Technologies and Novel Therapeutic Targets" session that will be held from 8.30 to 13.00 CET.  The presentation is entitled, "AQB-101, A novel glycoprotein with G-CSF activity and a recombinantly ligated amino acid sequence, demonstrates plasma pharmacokinetics comparable to PEG-G-CSF."

Dr. Chipman stated, "The data in this presentation demonstrates thepotential utility of Aequus' proprietary GlycoPolymer technology for extending the plasma half-life of therapeutically useful proteins and peptides that possess limited efficacy due to poor intrinsic pharmacokinetic properties.  Aequus believes that application of its straightforward modular GlycoPolymer technology approach, which utilizes industry standard methods and techniques, to biologically active proteins and peptides will facilitate the development of therapeutic protein-based drugs that require less frequent dosing and offer improved patient convenience." 

"Aequus' presentation will describe how the company has created a novel hG-CSF-based therapeutic protein candidate, AQB-101, by using the GlycoPolymer technology approach.  The AQB-101 glycoprotein possesses a plasma half-life that is comparable to pegylated hG-CSF (Neulasta®), and significantly prolonged compared to hG-CSF (Neupogen&
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the development and sale of patented biopharmaceutical medicine, modernized ... ingredients (API) today announced the business and development progress ... 1. Following the September 2014 JCM application (No. ...
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
Breaking Medicine Technology:TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... DC (PRWEB) January 22, 2015 Payday ... in vulnerable communities and cause financial distress to the ... by analysts at Howard University’s Center on Race and ... dollars in economic activity, payday loans at the same ...
(Date:1/22/2015)... January 22, 2015 Compare-autoinsurance.org has released a new ... by an auto insurance policy . , Some types ... Clients should check the newly released blog post to see if ... and dangerously damaged vehicles are some of the cars that cannot ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4
... PARK, N.J., Jan. 9 Managed Health Care,Associates, ... today,announced the addition of two outside members, Mr. ... MHA Board of Directors. Mr. Freedman and Mr.,Wheelan ... MHA,and Diamond Castle Holdings, LLC., Barry Freedman ...
... (OTC BB:ALRX -,News) stated on Tuesday that CEO Michael ... the open market, bringing the total number of,shares purchased ... confidence in the Company,s future., Mr. Michael Lee ... average price of $0.24 each, increasing his holdings to ...
... history of schizophrenia, social withdrawal among symptoms, study finds, , , ... to predict who will develop psychotic illnesses, such as schizophrenia ... new study says. , The study found five factors that ... disorder in children who were already at high risk of ...
... help simplify and refine search, SEATTLE, Jan. 9 ... an aging parent some adult children may be asking ... their loved ones., "That question often arises after ... said Eve Stern, RN, MS, president of,SNAPforSeniors, which has ...
... help employers, employees get more ... value from workplace benefits plans, COLUMBIA, S.C., ... has a new look -- and a clearer message.,Colonial Life ... tagline designed to better communicate who the company is and ...
... Jerusalem, Jan. 9. 2008 -- Two Hebrew University of ... have been awarded the 2008 Wolf Prize in Medicine ... expression and cancer research. , Minister of Education ... announced that the $100,000 prize, often referred to as ...
Cached Medicine News:Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 2Health News:MHA Announces: Managed Health Care Associates, Inc. (MHA) Expands Board of Directors 3Health News:5 Factors Help Predict Psychosis in Children 2Health News:5 Factors Help Predict Psychosis in Children 3Health News:Holiday Visits Nudge Many Towards Senior Housing Decision 2Health News:Holiday Visits Nudge Many Towards Senior Housing Decision 3Health News:Holiday Visits Nudge Many Towards Senior Housing Decision 4Health News:Holiday Visits Nudge Many Towards Senior Housing Decision 5Health News:New Colonial Life Brand Clarifies Company's Strengths 2Health News:New Colonial Life Brand Clarifies Company's Strengths 3Health News:2 Hebrew University scientists awarded Wolf Prizes 2
... from medium compression weight ... provides upper back compression ... the arms. Arm length ... Wonderfabric™ unraveling. Velcro® closing ...
Fully lined with cotton material for extra softness against patients skin. The 3 single adjustable soft Velcro® band provides,downward pressure preventing implants from moving upward or to the s...
This compression garment can be used for Breast Augmentation, Augmentation Mammaplasty, Trans Umbilical Breast Augmentation, Transaxillary Submuscular Augmentation....
Provides gentle compression above and below implants...
Medicine Products: